Lung Cancer
FDA Approves Ensartinib in ALK-Positive NSCLC
The FDA has granted ensartinib approval for adult patients with ALK-positive non–small cell lung cancer.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Sequencing and Management Considerations for ALK TKIs in NSCLC
During a Case-Based Roundtable® event, Chul Kim, MD, moderated a discussion on current use of ALK TKIs in lung cancer in the second article of a 2-part series.
The Future of Breast Cancer Care: Blackwood on Personalized Approaches
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Revolutionizing Lung Cancer Treatment: Advancements Offer New Hope
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed hope to millions worldwide.
Zenocutuzumab Now FDA-Approved in NRG1+ NSCLC and Pancreatic Cancer
With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.
